Merkel Cell Carcinoma Clinical Trial
Official title:
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
This study seeks to determine the safety and efficacy of shortening the primary and nodal adjuvant radiation therapy course from 2 Gy x 25 fractions to 3.6 Gy x 10 fractions in merkel cell carcinoma patients who may or may not be receiving immunotherapy.
- To estimate the 2-year local control rate for adjuvant hypofractionated RT to the primary tumor bed. - To estimate the 2-year nodal control rate for adjuvant hypofractionated RT to the primary draining nodal basin. Secondary Objectives - To determine MCC disease outcomes including:time to non-nodal locoregional recurrence, time to nodal recurrence, time to distant mestasis, disease-free-survival and disease-specific survival for patients receiving hypofractionated adjuvant RT. - To assess acute and late RT associated toxicity within or neighboring the radiated field. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT04705389 -
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
|
N/A | |
Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05429866 -
Immunological Variables Associated to ICI Toxicity in Cancer Patients
|
Phase 2 | |
Completed |
NCT03545334 -
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study
|
N/A | |
Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT04291885 -
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02054884 -
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04975152 -
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06039033 -
Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
|
||
Completed |
NCT02514824 -
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT04393753 -
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
|
Phase 2 | |
Recruiting |
NCT06056895 -
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT03370861 -
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
|
||
Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
Recruiting |
NCT03210935 -
French National Database of Rare Dermatological Cancers
|
||
Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06086288 -
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
|
Phase 2 |